Antisense Technology

Updated Clinical Trial Results for Cancer Therapies Presented

Published in Cancer Weekly, October 10th, 2000

Dr. Raymond P. Warrell, Jr., Genta Inc. (GNTA), presented an update of the company's ongoing clinical trials, along with plans for future registration studies that the company expects to initiate over the next six months.

He made his remarks at the Anticancer Biopharmaceuticals conference, held in San Francisco, California, during September 2000, and sponsored by Stephens, Inc.

Patient accrual to the company's ongoing Phase III trial of Genasense, Genta's lead antisense drug, in malignant melanoma remains on target for completion by mid-summer 2001. Warrell noted, "Long-term survival of patients in the original Phase I/II study now exceeds a median...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry